Limited effectiveness for the therapeutic blockade of interferon α in systemic lupus erythematosus: a possible role for type III interferons

Luis M Amezcua-Guerra; Diana Ferrusquía-Toriz; Diana Castillo-Martínez; Ricardo Márquez-Velasco; Adriana Karina Chávez-Rueda; Rafael Bojalil

doi:10.1093/rheumatology/keu020

Limited effectiveness for the therapeutic blockade of interferon α in systemic lupus erythematosus: a possible role for type III interferons

Rheumatology (Oxford). 2015 Feb;54(2):203-5. doi: 10.1093/rheumatology/keu020. Epub 2014 Mar 12.

Authors

Luis M Amezcua-Guerra¹, Diana Ferrusquía-Toriz², Diana Castillo-Martínez², Ricardo Márquez-Velasco², Adriana Karina Chávez-Rueda², Rafael Bojalil³

Affiliations

¹ Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Biological and Health Sciences, Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Department of Dermatology, Hospital General de Zona 1-A Dr Rodolfo Antonio de Mucha Macías and Immunology Unit, Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Biological and Health Sciences, Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Department of Dermatology, Hospital General de Zona 1-A Dr Rodolfo Antonio de Mucha Macías and Immunology Unit, Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Biological and Health Sciences, Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Department of Dermatology, Hospital General de Zona 1-A Dr Rodolfo Antonio de Mucha Macías and Immunology Unit, Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. lmamezcuag@gmail.com.
² Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Biological and Health Sciences, Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Department of Dermatology, Hospital General de Zona 1-A Dr Rodolfo Antonio de Mucha Macías and Immunology Unit, Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
³ Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Biological and Health Sciences, Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Department of Dermatology, Hospital General de Zona 1-A Dr Rodolfo Antonio de Mucha Macías and Immunology Unit, Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Biological and Health Sciences, Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Department of Dermatology, Hospital General de Zona 1-A Dr Rodolfo Antonio de Mucha Macías and Immunology Unit, Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

PMID: 24625504
DOI: 10.1093/rheumatology/keu020

No abstract available

Publication types

Editorial

MeSH terms

Humans
Interferon-alpha / antagonists & inhibitors*
Interferons / pharmacology*
Interleukins / pharmacology
Lupus Erythematosus, Systemic / drug therapy*
Signal Transduction / physiology
Treatment Failure

Substances

interferon-lambda, human
IFNL4 protein, human
Interferon-alpha
Interleukins
Interferons